FOLH1 and Familial prostate cancer: Notably, prostate-specific membrane antigen (PSMA)-targeted PET/CT has shown high accuracy, superior to other imaging modalities, for primary staging of high-risk prostate cancer patients [4, 5] as well as for staging after biochemical recurrence [6, 7].